Warfarin is widely used as a sole oral anticoagulant for the treatment and prevention of thromboembolic diseases. However, many reports have mentioned the defects of warfarin. It requires periodic monitoring because of its narrow therapeutic window and, in addition, warfarin interacts with many different foods and drugs. [4] [5] [6] Therefore, new anticoagulants based on novel mechanisms need to be developed. Recently, blood coagulation factor Xa (FXa) has attracted considerable attention as a novel anticoagulation target.
Warfarin is widely used as a sole oral anticoagulant for the treatment and prevention of thromboembolic diseases. However, many reports have mentioned the defects of warfarin. It requires periodic monitoring because of its narrow therapeutic window and, in addition, warfarin interacts with many different foods and drugs. [4] [5] [6] Therefore, new anticoagulants based on novel mechanisms need to be developed. Recently, blood coagulation factor Xa (FXa) has attracted considerable attention as a novel anticoagulation target.
FXa acts at the convergence point of the intrinsic pathway and the extrinsic pathway in a blood coagulation cascade. 7) FXa converts prothrombin into thrombin and leads to fibrin clot formation. It is thought that the inhibition of FXa effectively diminishes the thrombin generation and, as a result, leads to the inhibition of clot formation. Indeed, many FXa inhibitors have been synthesized and their anticoagulant activities reported. 8, 9) In these reports, FXa inhibitors exhibit less bleeding risk than warfarin and thrombin inhibitors. We have also conducted research to discover orally-active novel FXa inhibitors. [10] [11] [12] [13] Previously, we found that the series of cinnamyl derivatives represented by 1 and 2 produced potent in vitro FXa inhibitory activities and high selectivity. Moreover, these compounds also exhibited potent ex vivo anticoagulant activities in hamsters after oral administration.
However, regarding the chemical structure, these compounds are highly hydrophilic with two amidino groups. It seems that enhancement of these compounds' lipophilicity may improve the plasma concentration after oral administration and the resulting oral anticoagulant activity. Similarly, conversion of these compounds into their prodrug forms may be promising for high oral activity. Herein, we describe our synthetic efforts and further evaluations to discover R-142086 with ex vivo anticoagulant activity in dogs.
Chemistry Cinnamyl derivatives with various imidoyl group on the piperidine ring were synthesized as shown in Chart 1. Piperidine 3 13) was reacted with iminoethers 14, 15) under basic conditions, followed by acid hydrolysis to give corresponding bisamidine derivatives 4a-g. Other cinnamyl derivatives with a five-membered cyclic imidoyl group (6a, 6b) were synthesized by the same methods as compound 4d. Monoamidine derivatives were synthesized as shown in Chart 2. A t-butoxycarbonyl (Boc) group of compound 7 13) was converted to a methyl group (8a) by treatment with formaldehyde solution and formic acid. Compound 7 was also deprotected under an acidic condition to give piperidine 9. This compound was then subjected to a usual condition to give acetamide 8b. Piperidine 9 was converted to corresponding N-alkyl or N-aryl compounds (8c-k) by reductive amination with aldehydes or ketones (method A), or treatment with alkyl-or arylbromide under a basic condition (method B), or Pd-catalyzed amination with arylbromide and phosphine 10 (method C). 16) Reduction of the nitro group of compounds 8a-k afforded aniline 11a-k, respectively. An acetyl group of aniline 11b was converted to an ethyl group (11l) by the treatment with LiAlH 4 . These anilines 11a, 11c-l were subjected to methods similar to those of the other cinnamyl derivatives to give corresponding monoamidine derivatives 13a, 13c-l. A Boc group of known intermediate 14 13) was converted to N-(4-pyridylmethyl)piperidine compound 15 by 2 steps. This compound was also subjected to the similar methods described above to give corresponding monoamidine derivative 13m.
Prodrugs of monoamidine derivative 16 were synthesized as shown in Chart 3. Monoamidine derivative 16, synthesized as shown in Chart 2, was converted to its prodrugs 17a-i by the treatment with symmetric carbonates or 4-nitrophenyl carbonates. 17, 18) Benzonitrile 18, also synthesized as shown in Chart 2, was reacted with hydroxylamine under a basic condition to give amidoxime 17j. 3) Cinnamyl derivatives with a substituent on the double bond were synthesized as shown in Chart 4. In the case of intermediate 21 with a fluorine atom, 3-cyanobenzaldehyde (19) was subjected to a Horner-Wittig reaction to give (E)-20 and (Z)-20 as an undesired mixture ratio (E/Zϭ93/7). Then, treated with bromine, the mixture was isomerized to give (Z)-20 dominantly (E/Zϭ0.4/99.6). 19) This compound was treated with NaBH 4 to give Z-substituted fluoroallylalcohol 21. In the case of intermediate 22 with a methyl group, 3-cyanobenzaldehyde 19 was also reacted with ylide, followed by Luche reduction 20) to give (E)-substituted methylallylalcohol 22. Substituted allylalcohols 21 and 22 were coupled with sulfonamide 23, 24 and 25 by means of a Mitsunobu reaction 21) , followed by reactions similar to those of the other cinnamyl derivatives to give corresponding cinnamyl derivatives 26a-d.
Results and Discussion
The in vitro FXa and trypsin inhibitory activities of all the compounds were evaluated and expressed as IC 50 values. The ex vivo effects on prothrombin time (PT) in hamsters (per os (p.o.)) were also evaluated. Described above, this series of cinnamyl derivatives has two amidino groups in their structures. As a result, these compounds have high hydrophilicity. It seems that enhancement of these compounds' lipophilicity may improve their oral anticoagulant activity. As one of the approaches for the enhancement of lipophilicity, we attempted to remove the acetimidoyl group of these cinnamyl derivatives (Table 1) . 22) Non-substituted piperidine compounds with various substituent patterns on the central benzene ring (5a, 5b, 27, 3) 23) were synthesized and their biological activities were evaluated. Most of compounds exhibited significantly lower inhibitory activities than those of compound 1 and other acetimidoyl derivatives 13) in vitro. However, only chlorobenzene derivative 3 exhibited moderate in vitro FXa inhibitory activity. It seemed that the substituents on the benzene ring had a considerable effect on the FXa inhibitory activities of non-substituted piperidine compounds.
Based on the results shown in Table 1 , we synthesized monoamidine derivatives with non-amidine substituents i.e. alkyl, aryl, and arylalkyl groups on the nitrogen atom in the piperidine ring of chlorobenzene derivative 3, and evaluated their biological activities (Table 2) . Regarding alkyl derivatives (13a, c, d, e, l), these compounds exhibited potent FXa inhibitory activities (10-24 nM) in vitro. In particular, methyl derivative 13a and cyclopentyl derivative 13e also exhibited potent anticoagulant activities (ex vivo). On the other hand, phenyl derivative 13f exhibited significantly lower FXa inhibitory activity than those of alkyl derivatives. However, the introduction of an alkyl chain (13g, h) between the piperidine ring and a phenyl group of 13f, or conversion of one carbon atom on the phenyl group into a nitrogen atom (13i-k) improved the FXa inhibitory activities. Among them, 4-pyridyl derivative 13k exhibited potent in vitro FXa inhibitory activity comparable to that of the bisamidine derivative 1. However, in the ex vivo test by oral administration, compound 13k exhibited almost no oral anticoagulant activity. From these results, a methyl group (13a) and a cyclopentyl group (13e) were favorable at this position.
As another approach to improve the lipophilicity and oral activity of monoamidine derivatives, we intended to convert 13a to its prodrug form (Table 3) . Compound 16 with an ester group instead of a carboxylic group exhibited oral anticoagulant activity similar to that of compound 13a. Next, we attempted to convert an amidino moiety of compound 16 into its carbamate forms (17a-i) and amidoxime form (17j). Among these compounds, carbamate prodrugs 17a, 17b and amidoxime prodrug 17j exhibited anticoagulant activities (ex vivo) similar to that of compound 13a. However, as prodrugs, no advantages were observed. From the results shown in Tables 2 and 3, the conversion of bisamidine derivatives into monoamidine derivatives and their prodrugs could not improve the oral anticoagulant activity of bisamidine derivative 1.
As an alternative approach to improve the lipophilicity of bisamidine derivative 1, additional lipophilic imidoyl moieties other than an acetimidoyl group were introduced instead of an acetimidoyl group of compound 1, and their biological activities were evaluated (Table 4) . On the whole, most of the imidoyl compounds exhibited potent FXa inhibitory activi- ties in vitro. In particular, propioimidoyl (4a), benzimidoyl (4b), and five-membered cyclic imidoyl (4d) derivatives exhibited potent activities. Regarding cyclic imidoyl derivatives (4d-g), a tendency was observed indicating that a smaller ring size was suitable. In the ex vivo anticoagulant activities of these compounds, compound 4d was as potent as compound 1 (27 mg/kg). From these results, we found that the acetimidoyl and five-membered cyclic imidoyl groups were suitable as this part.
Based on the results shown in Table 4 , five-membered cyclic imidoyl derivatives 6a and 6b were synthesized and their biological activities were compared with those of corresponding acetimidoyl derivatives 28 and 2, which exhibited favorable results in the previous report 13) (Table 5 ). Compounds 6a and 6b exhibited potent FXa inhibitory activities in vitro. In addition, these compounds exhibited improved enzyme selectivity over trypsin. However, we examined the mutagenic potential of these cinnamyl derivatives and found that all the derivatives exhibited positive results in Ames tests. 24) On the other hand, the reported naphthylamidine derivative YM-75466 25) (Fig. 2 ) exhibited a negative result in the test. In terms of structural differences between YM-75466 and our derivatives, YM-75466 has a naphthyl moiety whereas our derivatives have cinnamyl moieties. Therefore, we speculated that the cause of the positive result was the oxidation of the double bond. Based on this speculation, we introduced substituents at the b-position of the cinnamyl moiety of compound 28 and their mutagenic potentials as well as biological activities were examined. As a result, both compound 26a with a fluorine atom and 26b with a methyl group exhibited negative results in Ames tests. Compound 26a also exhibited potent FXa inhibitory activity and oral anticoagulant activity similar to those of non-substituted derivative 28 in hamsters. To apply these findings to compounds 1 and 2, we synthesized 26c and 26d with a fluorine atom and evaluated their activities. Both compounds exhibited potent FXa inhibitory activities in vitro. In the ex vivo tests, however, compound 26c with a chlorine atom on the central benzene ring exhibited almost no oral anticoagulant activity. On the other hand, compound 26d with a carbamoyl group at this position exhibited potent anticoagulant activity in hamsters (33 mg/kg, p.o.). Moreover, compound 26d exhibited no mutagenic potential similar to those of 26a and 26b. 26 Vol. 57, No. 1 Cinnamyl derivatives with potent anticoagulant activities and no mutagenic potential (1, 26a, 26b, 26d) in addition to our reported compounds (29, 30) and YM-75466 (Fig. 2) were subjected to a pharmacokinetic study in dogs in order to assess the oral absorption of these derivatives (1 mg/kg) (Fig.  3) . Compounds 1 and 26a exhibited extremely low plasma concentrations, whereas compound 26d exhibited an obviously high plasma concentration superior to those of the other tested compounds.
Moreover, compound 26d exhibited a dose-dependent increase in plasma anti-FXa and anticoagulant activities after oral administration to dogs (Fig. 4) .
From these results, compound 26d (R-142086) has potent biological activities and a high plasma concentration by oral administration.
In conclusion, we synthesized many cinnamyl derivatives in order to develop compounds having potent oral anticoagulant activities. As a result, we found that cinnamyl derivatives with a fluorine atom or a methyl group on the double bond exhibited oral anticoagulant activities in hamsters and no mutagenic potential. Among them, 26d (R-142086) exhibited potent oral anti-FXa and anticoagulant activity in addition to a high plasma concentration compared to the other indoline and cinnamyl derivatives in dogs.
Experimental
Mass spectra were obtained on a JEOL LCmate spectrometer. 3-Chloro-4-(1-methylpiperidin-4-yloxy)nitrobenzene (8a) To a suspension of 4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloronitrobenzene 7 (1.50 g, 4.20 mmol) in 90% HCO 2 H (4.00 g) was added 37% HCHO solution (2.50 g) and the resulting mixture was stirred at 100°C for 2 h. The mixture was neutralized with K 2 CO 3 and extracted with EtOAc. The organic layer was washed with brine and dried. The organic layer was concentrated to give 8a (1.12 g, 4.14 mmol, 98%) as a yellow solid. 3-Chloro-4-(piperidin-4-yloxy)nitrobenzene (9) To a solution of 4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloronitrobenzene 7 (7.91 g, 22.2 mmol) in dioxane (80 ml) was added a 4 N solution of hydrogen chloride in dioxane (70 ml), and the resulting mixture was stirred overnight at room temperature. The mixture was concentrated and the resulting residue was dissolved in H 2 O. The mixture was neutralized with NaHCO 3 to give crystals and the crystals were collected by filtration to give 9 (8.06 g, quant.) as pale yellow needles. 4-(1-Acetylpiperidin-4-yloxy)-3-chloronitrobenzene (8b) To a solution of 3-chloro-4-(piperidin-4-yloxy)nitrobenzene 9 (1.00 g, 3.90 mmol) in pyridine (20 ml) was added Ac 2 O (0.550 ml, 5.82 mmol) and the mixture was stirred at room temperature for 3 h. H 2 O was added and the resulting mixture was extracted with EtOAc. The organic layer was washed with NaHCO 3 solution and brine. The organic layer was dried and concentrated to give 8b (1.05 g, 3.51 mmol, 90%) as a pale yellow solid. 
4-(1-Butylpiperidin-4-yloxy)-3-chloronitrobenzene (8d) (Method A)
To a solution of 3-chloro-4-(piperidin-4-yloxy)nitrobenzene 9 (1.50 g, 5.84 mmol) and butyraldehyde (1.04 ml, 11.5 mmol) in CH 2 Cl 2 (30 ml) were added AcOH (0.33 ml, 5.8 mmol) and NaBH 3 CN (0.18 g, 2.9 mmol) and the mixture was stirred at room temperature for 3 h. NaBH 3 CN (0.18 g, 2.9 mmol) was added and the mixture was stirred overnight at room temperature. The mixture was concentrated and the resulting residue was diluted with EtOAc. The organic solution was washed with H 2 O, NaHCO 3 solution and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ20/1) to give 8d (0.88 g, 2.81 mmol, 48%) as a yellow oil. 3-Chloro-4-(1-cyclopentylpiperidin-4-yloxy)nitrobenzene (8e) (Method B) To a solution of 3-chloro-4-(piperidin-4-yloxy)nitrobenzene 9 (4.00 g, 15.6 mmol) in DMF (70 ml) were added cyclopentyl bromide (1.96 ml, 18.3 mmol) and K 2 CO 3 (3.23 g, 23.4 mmol) and the mixture was stirred at 100°C for 7 h. Cyclopentyl bromide (0.700 ml, 6.53 mmol) was added and the mixture was stirred at 100°C for 2 h and at 120°C for 5 h. The mixture was diluted with EtOAc and washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ30/1-10/1) to give 8e (2.35 g, 7.13 mmol, 46%) as a yellow oil. 
3-Chloro-4-(1-ethylpiperidin-4-yloxy)aniline (11l)
A solution of 4-(1-acetylpiperidin-4-yloxy)-3-chloroaniline 11b (820 mg, 3.05 mmol) in THF (10 ml) was added to a suspension of LiAlH 4 (230 mg, 6.06 mmol) in THF (5 ml) and the mixture was refluxed for 3.5 h. LiAlH 4 (115 mg, 3.03 mmol) was added and the mixture was refluxed for 2 h. Na 2 SO 4 · 10H 2 O was added and the mixture was stirred overnight at room temperature. The mixture was filtered and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 
{N-[(E)-3-(3-Amidinophenyl)-2-propenyl]-N-[3-chloro-4-(1-methylpiperidin-4-yloxy)phenyl]sulfamoyl}acetic Acid Dihydrochloride (13a)
To a solution of 3-chloro-4-(1-methylpiperidin-4-yloxy)aniline 11a (6.95 g, 28.9 mmol) in CH 2 Cl 2 (150 ml) were added EtO 2 CCH 2 SO 2 Cl (3.88 ml, 28.9 mmol) and pyridine (4.67 ml, 57.7 mmol) and the mixture was stirred at room temperature for 5 h. H 2 O was added and the mixture was extracted with EtOAc. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /MeOHϭ4/1-1/1) to give ethyl {N-[3-chloro-4-(1-methylpiperidin-4-yloxy)phenyl]sulfamoyl}acetate (9.12 g, 23.3 mmol, 81%) as a brown amorphous solid. This amorphous solid (7.37 g, 18.9 mmol), (E)-3-(3-cyanophenyl)-2-propen-1-ol 12 (3.30 g, 20.7 mmol) and PPh 3 (5.93 g, 22.6 mmol) were dissolved in CH 2 Cl 2 (200 ml) and the mixture was treated with diethyl azodicarboxylate (DEAD) (3.49 ml, 22.2 mmol). The resulting mixture was stirred overnight at room temperature and the mixture was concentrated. The resulting residue was chromatographed on a silica gel column (EtOAc/MeOHϭ3/1-1/2) to give ethyl {N-[3-chloro-4-(1-methylpiperidin-4-yloxy)phenyl]-N-[(E)-3-(3-cyanophenyl)-2-propenyl]sulfamoyl}acetate (7.29 g, 13.7 mmol, 73%) as an orange amorphous solid. Into a solution of this amorphous solid (938 mg, 1.76 mmol) in CH 2 Cl 2 (30 ml) and EtOH (15 ml) was bubbled hydrogen chloride under ice-cooling, and the resulting mixture was stirred at room temperature under tightly sealed conditions for 5 h. The reaction mixture was concentrated and the resulting residue was dissolved in EtOH (20 ml). The solution was treated with NH 4 N-{3-Chloro-4-[1-(4-pyridylmethyl)piperidin-4-yloxy]phenyl}-N-[(E)-3-(3-cyanophenyl) 10 g, quant. ) as a pale yellow oil. This oil (1.10 g) was dissolved in DMF (30 ml) and treated with 4-(bromomethyl)pyridine hydrobromide (590 mg, 2.33 mmol) and K 2 CO 3 (590 mg, 4.27 mmol). The mixture was stirred overnight at room temperature and the mixture was diluted with EtOAc. The mixture was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (EtOAc/MeOHϭ10/1) to give 15 (970 mg, 1.60 mmol, 75%) as a pale yellow amorphous solid. (Z)-3-(3-Cyanophenyl)-2-fluoro-2-propen-1-ol (21) To a solution of ethyl 2-(diethylphosphono)-2-fluoroacetate (9.82 g, 40.5 mmol) in THF (160 ml) was added NaH (2.12 g, 48.6 mmol, as a 55% (w/w) dispersion in mineral oil) at Ϫ15°C and the mixture was stirred at Ϫ15°C for 10 min. 3-Cyanobenzaldehyde 19 (5.58 g, 42.6 mmol) in THF (40 ml) was added and the mixture was stirred at Ϫ15°C for 3 h. The reaction mixture was quenched with NH 4 Cl solution and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAc/CH 2 Cl 2 ϭ5/2/3) to give a mixture of (E)-and (Z)-20 (6.07 g, 27.7 mmol, 65%) as a colorless solid. This solid (6.07 g, 27.7 mmol) was dissolved in MeCN (100 ml), and the solution was treated with bromine (3 drops, catalytic amount). The resulting mixture was stirred at room temperature for 1 h and the mixture was concentrated to give (Z)-20 (6.03 g, 27.5 mmol, 99%) as a pale yellow solid. This solid (6.01 g, 27.4 mmol) was suspended in EtOH (100 ml) and the suspension was treated with NaBH 4 (2.07 g, 54.7 mmol). The mixture was stirred at 40°C for 1 h. NH 4 Cl solution was added and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAc/CH 2 Cl 2 ϭ4/3/3) to give 21 (4.12 g, 23.3 mmol, 85%) as a colorless solid. 6 mmol) in toluene (170 ml) was stirred at 70°C for 7 h and the reaction mixture was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 ) to give a yellow solid. This yellow solid was recrystallized from Et 2 O and hexane (1/9) to give (E)-3-(3-cyanophenyl)-2-methyl-2-propenal (5.19 g, 30.3 mmol, 80 %) as colorless crystals. These crystals (4.69 g, 27.4 mmol) were dissolved in CH 2 Cl 2 (30 ml) and EtOH (60 ml) and the mixture was treated with NaBH 4 (518 mg, 13.7 mmol) and CeCl 3 · 7H 2 O (3.57 g, 9.58 mmol). The mixture was stirred at 0°C for 2 h and then NaBH 4 (518 mg, 13.7 mmol) was added and the resulting mixture was stirred at 0°C for 1 h and quenched with NH 4 Cl solution. The mixture was then extracted with EtOAc and the organic layer was washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give 22 (4.50 g, 26.0 mmol, 95%) as a colorless oil. 04 g, 1.85 mmol, 41%) as a colorless amorphous solid. This amorphous solid (1.00 g, 1.78 mmol) was dissolved in EtOH (30 ml) and the mixture was treated with ethyl acetimidate hydrochloride (450 mg, 3.64 mmol) and Et 3 N (1.00 ml, 7.21 mmol). The resulting mixture was stirred overnight at room temperature and the reaction mixture was concentrated. The resulting residue was purified by a preparative HPLC (YMC-pack ODS, YMC Corp., H 2 O/MeCNϭ41/9) to give an amorphous solid. This amorphous solid was dissolved in a 1 N solution of hydrogen chloride (5.6 ml) and the mixture was concentrated to give ethyl (N-{4-[1-(acetimidoyl)piperidin-4-yloxy]-3-carbamoylphenyl}-N-[(Z)-3-(3-amidinophenyl)-2-fluoro-2-propenyl]sulfamoyl)acetate dihydrochloride (1.06 g, 1.57 mmol, 88%) as a colorless amorphous solid. This amorphous solid (910 mg, 1.35 mmol) was dissolved in a 3 N solution of hydrogen chloride (20 ml) and the mixture was stirred at 70°C for 3 h. The reaction mixture was concentrated and the resulting residue was purified by a preparative HPLC (YMC-pack ODS, YMC Corp., H 2 O/MeCNϭ9/1) to give an amorphous solid. This amorphous solid was dissolved in a 1 N solution of hydrogen chloride (4 ml) and the mixture was concentrated. 
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